WO2022115052A1 - Improved wet granulation processes for apixaban comprising formulations - Google Patents
Improved wet granulation processes for apixaban comprising formulations Download PDFInfo
- Publication number
- WO2022115052A1 WO2022115052A1 PCT/TR2020/051185 TR2020051185W WO2022115052A1 WO 2022115052 A1 WO2022115052 A1 WO 2022115052A1 TR 2020051185 W TR2020051185 W TR 2020051185W WO 2022115052 A1 WO2022115052 A1 WO 2022115052A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- solid oral
- oral pharmaceutical
- apixaban
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 229960003886 apixaban Drugs 0.000 title claims abstract description 78
- 238000005550 wet granulation Methods 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 43
- 238000009472 formulation Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims description 28
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 26
- 238000005469 granulation Methods 0.000 claims description 21
- 230000003179 granulation Effects 0.000 claims description 21
- 239000011230 binding agent Substances 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 18
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 229940069328 povidone Drugs 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229960001021 lactose monohydrate Drugs 0.000 claims description 5
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 206010014522 Embolism venous Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000011540 hip replacement Methods 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 210000003127 knee Anatomy 0.000 claims description 3
- 238000013150 knee replacement Methods 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 208000004043 venous thromboembolism Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 16
- 239000003826 tablet Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 108010074860 Factor Xa Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940047562 eliquis Drugs 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salt thereof has a D90 less than 20 microns and at least one pharmaceutically acceptable excipient manufactured by using wet granulation method wherein Apixaban is in non-hydrolyzed form.
- Apixaban is novel, orally active, selective inhibitor of the coagulation factor Xa (FXa) which directly and reversibly binds to the active site of FXa, and decreases the conversion of prothrombin to thrombin due to exerting antithrombotic and anticoagulant effects.
- FXa coagulation factor Xa
- Apixaban drug substance is a white to pale yellow, non-hygroscopic crystalline powder and a non-ionizable compound which means that, any changes in pH does not affect to the aqueous solubility of Apixaban.
- the molecule has no chiral central, therefore, no stereoisomers exist. It shows polymorphism and a number of hydrates and solvates were identified. However, only one form is consistently produced by the proposed synthetic process.
- Apixaban was firstly commercially authorized by the European Medicines Agency in May 2011. The medicinal product of it been launched in the film-coated tablet form under the name of the ELIQUIS® which is used for the treatment for preventing venous thromboembolism in adults following elective knee or hip replacement surgery and for reducing the risk of stroke or systemic embolism in adults with non-valvular atrial fibrillation.
- ELIQUIS ® film coated tablets are available for oral administration in strengths of 2.5 mg and 5 mg of Apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.
- the film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetine, and yellow iron oxide for 2.5 mg tablets or red iron oxide for 5 mg tablets.
- Absorption of apixaban is approximately 50%. Peak plasma concentrations are observed around 3 to 4 hours post dose after oral following administration. 87% of Apixaban is bound to the plasma proteins. By being prolonged absorption, the pharmacokinetics of Apixaban are complicated. Its short clearance half-life is about 6 hours, but the apparent half-life during following dose is about 12 hours. Thus, it continues the anticoagulation effective for at least a day, even when the drug is stopped for surgery. Its absorption takes place throughout the gastrointestinal tract. Food does not significantly affect bioavailability of Apixaban, thus; it can be taken without to food.
- BMS Bristol-Myers Squibb
- Pfizer as an anticoagulant and antithrombotic agent.
- Apixaban base and its pharmaceutically acceptable salts first have been declared in EP1427415.
- Example 18 at the EP1427415 discloses the preparation of Apixaban base.
- EP2538925 relates to a pharmaceutical composition
- a pharmaceutical composition comprising crystalline Apixaban particles having a D90 equal to or less than 89 pm and a pharmaceutically acceptable diluent or carrier excipients wherein the prepared composition is manufactured by using a dry granulation process.
- EP2538925 patent document has many divisional applications.
- One of the divisional application EP3017811 discloses to the dry granulation process steps of the prepared pharmaceutical formulations comprising Apixaban and a pharmaceutically acceptable diluent or carrier excipients.
- Another divisional application EP3251660 discloses to a pharmaceutical composition comprising crystalline Apixaban particles having a D90 less than 50 pm and a pharmaceutically acceptable diluent or carrier excipients.
- Another divisional application EP3246021 discloses to a pharmaceutical composition exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the dissolution test is performed in an aqueous media buffered to a pH range 1 to 7.4 and controlled at 37°C.
- Another divisional application EP3257500 discloses to a pharmaceutical composition
- a pharmaceutical composition comprising crystalline Apixaban particles and a pharmaceutically acceptable diluent or carrier and a surfactant, wherein the surfactant is present in a concentration of 0.25% to 2% by weight, also wherein the composition is manufactured by using an air-jet milling process to reduce Apixaban particle size to the desired size and dry granulation.
- Another divisional application EP3643301 discloses to a pharmaceutical composition exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the dissolution test is performed in 900 mL of dissolution medium containing 0.05 M sodium phosphate at pH 6.8 with 0.05% SDS at 37°C using USP Apparatus 2 (paddles) at a rotation speed of 50-75 rpm.
- EP3662899 is rather close with the EP3643301 patent document wherein EP3662899 patent document discloses to the dose/solubility ratio of the Apixaban in the tablet which is less than 250 mL.
- the given dissolution properties are same with the EP3643301 patent document.
- EP3405195 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable polymer wherein the polymer is graft copolymer of polyvinyl caprolactam, polyvinyl acetate and polyethylene glycol obtained by using of hot-melt method.
- WO2019177318 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban was prepared according to a preparation method comprising the steps of; mixing Apixaban and a water- soluble polymer to prepare a mixture; and wet kneading and vacuum drying of the mixture.
- WO2017221209 relates to a pharmaceutical composition
- a pharmaceutical composition comprising the crystalline Apixaban particles having a D90 value more than 89 microns and a pharmaceutically acceptable carrier wherein the crystalline Apixaban is Form M.
- EP3243505 relates to a pharmaceutical composition comprising amorphous Apixaban or a salt thereof together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits an in vitro dissolution profile measured in phosphate buffer at pH 6.8 containing 0.05 % weight/volume of sodium lauryl sulfate according to which: at least 30% of Apixaban is dissolved after 5 minutes and at least 60% of Apixaban is dissolved after 10 minutes.
- EP2907507 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban and a particularly selected polymer having low viscosity as binder.
- W02017163170 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban prepared by a non-aqueous wet granulation process wherein the composition releases at least 80% of Apixaban in 30 minutes.
- EP3107530 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban and a polymer having low viscosity as binder wherein the polymer is selected from the group consisting of povidone, hypromellose, hydroxypropyl cellulose, polyvinyl alcohol, copovidone, polyvinyl alcohol-polyethylene glycol graft copolymer, respectively having low viscosity, and a mixture thereof and wherein the composition prepared by wet granulation process.
- W02017121340 relates to a pharmaceutical composition
- a pharmaceutical composition comprising non-micronized Apixaban and pharmaceutically acceptable excipients wherein the povidone is selected as binder as is dissolved in DMSO.
- EP2554159 relates to a pharmaceutical composition comprising micronized Apixaban and a content uniformity enhancer manufactured by using direct compression.
- WO2017182908 relates to a pharmaceutical composition comprising micronized Apixaban and pharmaceutically acceptable excipients manufactured by using direct compression wherein the amount of the micronized Apixaban is present up to 20% of the total weight.
- EP3582777 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban having a D90 particle size of more than 100 microns, a diluent, a surfactant, a disintegrant and a lubricant manufactured by using wet granulation method wherein Apixaban is dispersed in the binder solution.
- TR2017/17703 relates to a pharmaceutical composition
- a pharmaceutical composition comprising Apixaban or a pharmaceutically acceptable salt thereof manufactured by using wet granulation method wherein Apixaban is dispersed into the solvent or solvent mixture to prepare the granulating solution.
- composition comprising Apixaban particles having a D90 value less than 20 microns and at least one pharmaceutically acceptable excipient is developed in the immediate release oral solid dosage form with improved solubility by using wet granulation method wherein Apixaban is in non-hydrolyzed form.
- the object of this invention is to develop an immediate release solid oral pharmaceutical composition
- a therapeutically effective amount of Apixaban which is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa.
- It is an object of the present invention is to develop a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salts, which is used for the treatment for preventing venous thromboembolism in adults following elective knee or hip replacement surgery and for reducing the risk of stroke or systemic embolism in adults with non-valvular atrial fibrillation.
- the object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban and pharmaceutically acceptable excipients, wherein the Apixaban is in particulate and crystalline form and has a D90 value less than 20 microns.
- Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban which can be manufactured into solid oral dosage forms, such as tablets having desired dissolution profiles.
- Another object of the present invention is to provide a solid oral pharmaceutical composition comprising crystalline Apixaban and one or more pharmaceutically acceptable excipients manufactured by using wet granulation method.
- Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban manufactured by using wet granulation method wherein provided for the manufacture of tablets containing the active ingredient, filler, disintegrant, binder, lubricant, surfactant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
- Also present invention particularly relates to a process for the preparation of a pharmaceutical composition manufactured by using wet granulation method, including the steps of: a. Apixaban, Lactose monohydrate, Croscarmellose sodium, Microcrystalline cellulose and specified amount of Povidone are screened through a proper sieve, transferred into the high shear mixer through screening with a proper sieve and stirred, b. Poloxamer is dissolved in a sufficient amount of the deionized water till to dissolve completely, c. The rest amount of the Povidone is added into the granulation solution prepared in Step b and stirred till to obtain homogenous mixture, d. The solution in Step c is added into the powder blend prepared in Step a to perform granulation process, e.
- the granule prepared in Step d is dried in solution bed dryer and shifted through a proper sieve, f.
- Magnesium stearate is screened through a proper sieve and added to the powder granulation prepared in Step e and are stirred to obtain a uniform final blend, g. Tablet compression was performed with the final blend in Step f.
- Another object of the present invention is to provide a solid oral pharmaceutical composition
- a solid oral pharmaceutical composition comprising Apixaban particles having a D90 value less than 20 microns and at least one pharmaceutically acceptable excipients manufactured by using wet granulation method and Apixaban is in non-hydrolyzed form.
- the present invention provides a pharmaceutical composition comprising Apixaban and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form wherein the prepared composition is manufactured by using wet granulation method to get desired dissolution properties.
- a pharmaceutical composition comprising Apixaban and at least one pharmaceutically acceptable excipients wherein Apixaban particles have a D90 value less than 20 microns.
- D90 is defined as 90% of the volume of particles having a diameter less than a specified diameter.
- the value of D90 refers to the particle size distribution of Apixaban particles.
- Apixaban particles having D90 doesn’t exceed the 20 microns, preferably D90 is less than 17 microns, more preferably D90 is less than 15 microns.
- Apixaban is present as a low dose drug as constituting less than 5% w/w by the total weight of the composition.
- manufacturing methods are composed of direct compression, dry granulation and wet granulation methods.
- the manufacturing step is selected as wet granulation method.
- Wet granulation method refers to convert a powder blend into granules with having suitable flow and cohesive properties for tableting.
- the procedure consists of preparing the granulating solution of a binder or any other excipient dissolved in suitable solvent; mixing the powders in a suitable blender wherein the active ingredient and at least one other pharmaceutically excipient present and adding/spraying the granulating solution onto to the powder blend, usually high shear or fludizied bed to obtain a granulation.
- the granulation takes place in the high shear granulator.
- the advantages of wet granulation include improvement of the cohesiveness and compressibility of powders, a good distribution and uniform content of micronized or finely milled low-dosage drugs.
- a preferred embodiment of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban having a D90 less than 20 microns by using wet granulation method.
- the prepared pharmaceutically composition is also provided for the manufacture of tablets containing the active ingredient, filler, disintegrant, binder, lubricant, surfactant and solvent for the immediate release solid dosage form.
- the pharmaceutical composition comprising at least one filler which can be selected from dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose anhydrous, lactose monohydrate, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
- filler is the combination of lactose anhydrous and microcrystalline cellulose.
- the pharmaceutical composition comprising at least one disintegrant which can be selected from croscarmei!ose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
- the disintegrant is croscarmellose sodium.
- the pharmaceutical composition comprises at least a binder which can be selected from hypromeliose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof.
- the binder is povidone.
- the pharmaceutical composition comprising at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
- the lubricant is magnesium stearate.
- Typical granulation solutions usually selected as water, ethanol, isopropanol and methylene chloride either alone or in combination. Also, it can be used alone or, more usually, as a solvent containing a dissolved binder/suspension/gelatinized binder to ensure particle adhesion once the granule is dry.
- preferred solvent in the granulation solution is selected as water.
- preferred solvent in the granulation solution contains binder and surfactant.
- Surfactant is used in tablet formulation to increase the dissolution rate or active ingredient release amount by increasing hydrophilicity within the tablet matrix.
- the pharmaceutical composition comprising at least one suitable surfactant which is selected from polyoxyethylene fatty alcohol ethers, sorbitan fatty acid esters, stearyl alcohol, poloxamers, potassium laureate, sodium lauryl sulfate, benzalkonium chloride and mixtures thereof.
- the surfactant is poloxamer.
- the pharmaceutical composition of the present invention is manufactured by using wet granulation method, wherein the process comprised the steps of: a. Co-sifting Apixaban, filler, disintegrant and specified amount of the binder through a proper sieve and stir to prepare the powder blend, b. Dissolving the surfactant in the granulation solution, c. Preparing the binder solution by adding it into the prepared granulation solution in Step b, d. Adding the binder solution into the prepared pow'der blend in Step a to preform granulation process, e. Drying the granules in fludizied bed dryer and sifting the dried granules through a proper sieve, f. Sifting the lubricant through a proper sieve and adding to the prepared granule in Step e, g, Compressing the final blend in Step f.
- the embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation method.
- Example 1 was given in the Table- 1 below.
- the proposed embodiment based on the invention provides an immediate release oral solid pharmaceutical composition wherein the amounts in w/w% by w'eight of the total composition are as stated below: Table 1: Unit Formula of Example 1
- the process for the preparation of a pharmaceutical composition manufactured by using wet granulation method including the steps of: a. Apixaban, Lactose monohydrate, Croscarmellose sodium, Microcrystalline cellulose and specified amount of Povidone are screened through a proper sieve, transferred into the high shear mixer and stirred, b. Poloxamer is dissolved in a sufficient amount of the deionized water till to dissolve completely, c. The rest amount of the Povidone is added into the granulation solution prepared in Step b and stirred till to obtain homogenous mixture, d. The solution in Step c is added into the powder blend prepared in Step a to perform granulation process, e.
- the granule prepared in Step d is dried in fludizied bed dryer and shifted through a proper sieve, f.
- Magnesium stearate is screened through a proper sieve and added to the powder granulation prepared in Step e and are stirred to obtain a uniform final blend, g. Tablet compression is performed with the final blend in Step f.
- the obtained tablets were subjected to in vitro dissolution study and the dissolution conditions were designated considering the gastrointestinal pathway of orally applied solid dosage forms.
- the dissolution test is carried out at pH 6.8 phosphate buffer containing 0.05% sodium lauryl sulfate. Other conditions are defined as; volume of dissolution media is 900 ml, temperature is 37°C ⁇ 0.5°C, rotation speed is 75 rpm, apparatus is paddle and the duration of dissolution study is 60-minute. Table 2: The results of dissolution study of Example 1
- Example 1 Based on the results presented in Table 1 above, the in-vitro dissolution results of Example 1 were similar with the Reference drug product.
- similarity of two drug products can be compared based on the results of in vitro dissolution profile studies of these drug products by using a similarity factor f 2 .
- the similarity factor f 2 is the most common comparison index and if the estimated value is in the range from 50 to 100, the dissolution profiles of two drug products in comparison are concluded as similar.
- the similarity factor f 2 of Example 1 was calculated as 78.0, wherein the first sample was taken after 10 minutes, which means the developed formulation was suitable and the prepared pharmaceutical composition is proper as it was intended.
- the proper dissolution profile was obtained which was developed in the immediate release dosage form comprising Apixaban having a D90 value less than 20 microns and at least one pharmaceutical excipient manufactured by using wet granulation method, wherein Apixaban was only present in the powder blend and binder solution was made of dissolved povidone and poloxamer which enable the aqueous povidone-based binder solution to decrease the interfacial tension between the poorly soluble Apixaban particles.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salt thereof has a D90 less than 20 microns and at least one pharmaceutically acceptable excipient manufactured by using wet granulation method wherein Apixaban is in non-hydrolyzed form.
Description
IMPROVED WET GRANULATION PROCESSES FOR APIXABAN COMPRISING
FORMULATIONS
FIELD OF INVENTION
The present invention relates to a pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salt thereof has a D90 less than 20 microns and at least one pharmaceutically acceptable excipient manufactured by using wet granulation method wherein Apixaban is in non-hydrolyzed form.
STATE OF ART
Apixaban is novel, orally active, selective inhibitor of the coagulation factor Xa (FXa) which directly and reversibly binds to the active site of FXa, and decreases the conversion of prothrombin to thrombin due to exerting antithrombotic and anticoagulant effects.
The chemical name of Apixaban is described as l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-l- piperidinyl) phenyl]-4, 5, 6, 7-tetrahydro-lH-pyrazolo [3, 4-c] pyridine-3-carboxamide. The molecular formula of which is C25H25N5O4, its relative molecular mass 459.50 and its structural formula is shown in the Formula I.
Formula I
Apixaban drug substance is a white to pale yellow, non-hygroscopic crystalline powder and a non-ionizable compound which means that, any changes in pH does not affect to the aqueous solubility of Apixaban.
The molecule has no chiral central, therefore, no stereoisomers exist. It shows polymorphism and a number of hydrates and solvates were identified. However, only one form is consistently produced by the proposed synthetic process.
Apixaban was firstly commercially authorized by the European Medicines Agency in May 2011. The medicinal product of it been launched in the film-coated tablet form under the name of the ELIQUIS® which is used for the treatment for preventing venous thromboembolism in
adults following elective knee or hip replacement surgery and for reducing the risk of stroke or systemic embolism in adults with non-valvular atrial fibrillation.
ELIQUIS® film coated tablets are available for oral administration in strengths of 2.5 mg and 5 mg of Apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetine, and yellow iron oxide for 2.5 mg tablets or red iron oxide for 5 mg tablets.
Absorption of apixaban is approximately 50%. Peak plasma concentrations are observed around 3 to 4 hours post dose after oral following administration. 87% of Apixaban is bound to the plasma proteins. By being prolonged absorption, the pharmacokinetics of Apixaban are complicated. Its short clearance half-life is about 6 hours, but the apparent half-life during following dose is about 12 hours. Thus, it continues the anticoagulation effective for at least a day, even when the drug is stopped for surgery. Its absorption takes place throughout the gastrointestinal tract. Food does not significantly affect bioavailability of Apixaban, thus; it can be taken without to food.
Apixaban was co-developed by Bristol-Myers Squibb (BMS) and Pfizer as an anticoagulant and antithrombotic agent.
Apixaban base and its pharmaceutically acceptable salts first have been declared in EP1427415. In particular, Example 18 at the EP1427415 discloses the preparation of Apixaban base.
In the state of art there are many patents/patent applications which are summarized below.
EP2538925 relates to a pharmaceutical composition comprising crystalline Apixaban particles having a D90 equal to or less than 89 pm and a pharmaceutically acceptable diluent or carrier excipients wherein the prepared composition is manufactured by using a dry granulation process.
EP2538925 patent document has many divisional applications.
One of the divisional application EP3017811 discloses to the dry granulation process steps of the prepared pharmaceutical formulations comprising Apixaban and a pharmaceutically acceptable diluent or carrier excipients.
Another divisional application EP3251660 discloses to a pharmaceutical composition comprising crystalline Apixaban particles having a D90 less than 50 pm and a pharmaceutically acceptable diluent or carrier excipients.
Another divisional application EP3246021 discloses to a pharmaceutical composition exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the dissolution test is performed in an aqueous media buffered to a pH range 1 to 7.4 and controlled at 37°C.
Another divisional application EP3257500 discloses to a pharmaceutical composition comprising crystalline Apixaban particles and a pharmaceutically acceptable diluent or carrier and a surfactant, wherein the surfactant is present in a concentration of 0.25% to 2% by weight, also wherein the composition is manufactured by using an air-jet milling process to reduce Apixaban particle size to the desired size and dry granulation.
Another divisional application EP3643301 discloses to a pharmaceutical composition exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the dissolution test is performed in 900 mL of dissolution medium containing 0.05 M sodium phosphate at pH 6.8 with 0.05% SDS at 37°C using USP Apparatus 2 (paddles) at a rotation speed of 50-75 rpm.
Another divisional application EP3662899 is rather close with the EP3643301 patent document wherein EP3662899 patent document discloses to the dose/solubility ratio of the Apixaban in the tablet which is less than 250 mL. The given dissolution properties are same with the EP3643301 patent document.
EP3405195 relates to a pharmaceutical composition comprising Apixaban or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable polymer wherein the polymer is graft copolymer of polyvinyl caprolactam, polyvinyl acetate and polyethylene glycol obtained by using of hot-melt method.
WO2019177318 relates to a pharmaceutical composition comprising Apixaban was prepared according to a preparation method comprising the steps of; mixing Apixaban and a water- soluble polymer to prepare a mixture; and wet kneading and vacuum drying of the mixture.
WO2017221209 relates to a pharmaceutical composition comprising the crystalline Apixaban particles having a D90 value more than 89 microns and a pharmaceutically acceptable carrier wherein the crystalline Apixaban is Form M.
EP3243505 relates to a pharmaceutical composition comprising amorphous Apixaban or a salt thereof together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits an in vitro dissolution profile measured in phosphate buffer at pH 6.8 containing 0.05 % weight/volume of sodium lauryl sulfate according to which: at least 30% of Apixaban is dissolved after 5 minutes and at least 60% of Apixaban is dissolved after 10 minutes.
EP2907507 relates to a pharmaceutical composition comprising Apixaban and a particularly selected polymer having low viscosity as binder.
W02017163170 relates to a pharmaceutical composition comprising Apixaban prepared by a non-aqueous wet granulation process wherein the composition releases at least 80% of Apixaban in 30 minutes.
EP3107530 relates to a pharmaceutical composition comprising Apixaban and a polymer having low viscosity as binder wherein the polymer is selected from the group consisting of povidone, hypromellose, hydroxypropyl cellulose, polyvinyl alcohol, copovidone, polyvinyl alcohol-polyethylene glycol graft copolymer, respectively having low viscosity, and a mixture thereof and wherein the composition prepared by wet granulation process.
W02017121340 relates to a pharmaceutical composition comprising non-micronized Apixaban and pharmaceutically acceptable excipients wherein the povidone is selected as binder as is dissolved in DMSO.
EP2554159 relates to a pharmaceutical composition comprising micronized Apixaban and a content uniformity enhancer manufactured by using direct compression.
WO2017182908 relates to a pharmaceutical composition comprising micronized Apixaban and pharmaceutically acceptable excipients manufactured by using direct compression wherein the amount of the micronized Apixaban is present up to 20% of the total weight.
EP3582777 relates to a pharmaceutical composition comprising Apixaban having a D90 particle size of more than 100 microns, a diluent, a surfactant, a disintegrant and a lubricant manufactured by using wet granulation method wherein Apixaban is dispersed in the binder solution.
TR2017/17703 relates to a pharmaceutical composition comprising Apixaban or a pharmaceutically acceptable salt thereof manufactured by using wet granulation method
wherein Apixaban is dispersed into the solvent or solvent mixture to prepare the granulating solution.
Based on the prior art given in the above, many formulation strategies have been carried out to overcome the solubility and bioavailability problem of Apixaban by determining proper particle size and manufacturing process. However, there still exists a need in the art for an improved pharmaceutical composition and dosage form comprising apixaban and improved technological process for the preparation thereof.
In the present invention, pharmaceutical composition comprising Apixaban particles having a D90 value less than 20 microns and at least one pharmaceutically acceptable excipient is developed in the immediate release oral solid dosage form with improved solubility by using wet granulation method wherein Apixaban is in non-hydrolyzed form.
SUMMARY OF INVENTION
The object of this invention is to develop an immediate release solid oral pharmaceutical composition comprising a therapeutically effective amount of Apixaban, which is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa.
It is an object of the present invention is to develop a solid oral pharmaceutical composition comprising Apixaban or one of its pharmaceutically acceptable salts, which is used for the treatment for preventing venous thromboembolism in adults following elective knee or hip replacement surgery and for reducing the risk of stroke or systemic embolism in adults with non-valvular atrial fibrillation.
The object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban and pharmaceutically acceptable excipients, wherein the Apixaban is in particulate and crystalline form and has a D90 value less than 20 microns.
Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban which can be manufactured into solid oral dosage forms, such as tablets having desired dissolution profiles.
Another object of the present invention is to provide a solid oral pharmaceutical composition comprising crystalline Apixaban and one or more pharmaceutically acceptable excipients manufactured by using wet granulation method.
Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban manufactured by using wet granulation method wherein provided for the manufacture of tablets containing the active ingredient, filler, disintegrant, binder, lubricant, surfactant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
Also present invention particularly relates to a process for the preparation of a pharmaceutical composition manufactured by using wet granulation method, including the steps of: a. Apixaban, Lactose monohydrate, Croscarmellose sodium, Microcrystalline cellulose and specified amount of Povidone are screened through a proper sieve, transferred into the high shear mixer through screening with a proper sieve and stirred, b. Poloxamer is dissolved in a sufficient amount of the deionized water till to dissolve completely, c. The rest amount of the Povidone is added into the granulation solution prepared in Step b and stirred till to obtain homogenous mixture, d. The solution in Step c is added into the powder blend prepared in Step a to perform granulation process, e. The granule prepared in Step d is dried in solution bed dryer and shifted through a proper sieve, f. Magnesium stearate is screened through a proper sieve and added to the powder granulation prepared in Step e and are stirred to obtain a uniform final blend, g. Tablet compression was performed with the final blend in Step f.
Another object of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban particles having a D90 value less than 20 microns and at least one pharmaceutically acceptable excipients manufactured by using wet granulation method and Apixaban is in non-hydrolyzed form.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical composition comprising Apixaban and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form wherein the prepared composition is manufactured by using wet granulation method to get desired dissolution properties.
Based on the prior art, even if Apixaban is classified as BCS (Biopharmaceutics Classification System) class III compound which means that it exhibits high solubility and low permeability
less than 10 mg Apixaban, it acts as being poor solubility in water as 0.028 mg/mL at 24°C. Thus, the stated particle size with proper manufacturing method becomes an essential and important issue to get completed and desired dissolution profile.
In the present invention relates to a pharmaceutical composition comprising Apixaban and at least one pharmaceutically acceptable excipients wherein Apixaban particles have a D90 value less than 20 microns.
The term “D90” is defined as 90% of the volume of particles having a diameter less than a specified diameter. The value of D90 refers to the particle size distribution of Apixaban particles. In the present invention, Apixaban particles having D90 doesn’t exceed the 20 microns, preferably D90 is less than 17 microns, more preferably D90 is less than 15 microns.
In the present invention, Apixaban is present as a low dose drug as constituting less than 5% w/w by the total weight of the composition. Thus, to eliminate the forming of the non-uniform content in the tablet composition, proper manufacturing method should be selected. Conventionally, manufacturing methods are composed of direct compression, dry granulation and wet granulation methods. In the present invention, the manufacturing step is selected as wet granulation method.
Wet granulation method refers to convert a powder blend into granules with having suitable flow and cohesive properties for tableting. The procedure consists of preparing the granulating solution of a binder or any other excipient dissolved in suitable solvent; mixing the powders in a suitable blender wherein the active ingredient and at least one other pharmaceutically excipient present and adding/spraying the granulating solution onto to the powder blend, usually high shear or fludizied bed to obtain a granulation. In the present invention, the granulation takes place in the high shear granulator. The advantages of wet granulation include improvement of the cohesiveness and compressibility of powders, a good distribution and uniform content of micronized or finely milled low-dosage drugs.
In a preferred embodiment of the present invention is to provide a solid oral pharmaceutical composition comprising Apixaban having a D90 less than 20 microns by using wet granulation method.
Moreover, the prepared pharmaceutically composition is also provided for the manufacture of tablets containing the active ingredient, filler, disintegrant, binder, lubricant, surfactant and solvent for the immediate release solid dosage form.
In a preferred embodiment, the pharmaceutical composition comprising at least one filler which can be selected from dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose anhydrous, lactose monohydrate, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof. Preferably, filler is the combination of lactose anhydrous and microcrystalline cellulose.
In a preferred embodiment, the pharmaceutical composition comprising at least one disintegrant which can be selected from croscarmei!ose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose. Preferably, the disintegrant is croscarmellose sodium.
In a preferred embodiment, the pharmaceutical composition comprises at least a binder which can be selected from hypromeliose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof. Preferably, the binder is povidone.
In a preferred embodiment, the pharmaceutical composition comprising at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof. Preferably, the lubricant is magnesium stearate.
The choice of the granulating solvent is one of the critical step for the granulation. Typical granulation solutions usually selected as water, ethanol, isopropanol and methylene chloride either alone or in combination. Also, it can be used alone or, more usually, as a solvent containing a dissolved binder/suspension/gelatinized binder to ensure particle adhesion once the granule is dry.
In the present invention, preferred solvent in the granulation solution is selected as water. Moreover, in the present invention, preferred solvent in the granulation solution contains binder
and surfactant. Surfactant is used in tablet formulation to increase the dissolution rate or active ingredient release amount by increasing hydrophilicity within the tablet matrix.
In a preferred embodiment, the pharmaceutical composition comprising at least one suitable surfactant which is selected from polyoxyethylene fatty alcohol ethers, sorbitan fatty acid esters, stearyl alcohol, poloxamers, potassium laureate, sodium lauryl sulfate, benzalkonium chloride and mixtures thereof. Preferably, the surfactant is poloxamer.
One of the preferred embodiment, the pharmaceutical composition of the present invention is manufactured by using wet granulation method, wherein the process comprised the steps of: a. Co-sifting Apixaban, filler, disintegrant and specified amount of the binder through a proper sieve and stir to prepare the powder blend, b. Dissolving the surfactant in the granulation solution, c. Preparing the binder solution by adding it into the prepared granulation solution in Step b, d. Adding the binder solution into the prepared pow'der blend in Step a to preform granulation process, e. Drying the granules in fludizied bed dryer and sifting the dried granules through a proper sieve, f. Sifting the lubricant through a proper sieve and adding to the prepared granule in Step e, g, Compressing the final blend in Step f.
The embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation method.
The embodiment, Example 1 was given in the Table- 1 below. The proposed embodiment based on the invention provides an immediate release oral solid pharmaceutical composition wherein the amounts in w/w% by w'eight of the total composition are as stated below:
Table 1: Unit Formula of Example 1
Further in a preferred embodiment, the process for the preparation of a pharmaceutical composition manufactured by using wet granulation method, including the steps of: a. Apixaban, Lactose monohydrate, Croscarmellose sodium, Microcrystalline cellulose and specified amount of Povidone are screened through a proper sieve, transferred into the high shear mixer and stirred, b. Poloxamer is dissolved in a sufficient amount of the deionized water till to dissolve completely, c. The rest amount of the Povidone is added into the granulation solution prepared in Step b and stirred till to obtain homogenous mixture, d. The solution in Step c is added into the powder blend prepared in Step a to perform granulation process, e. The granule prepared in Step d is dried in fludizied bed dryer and shifted through a proper sieve, f. Magnesium stearate is screened through a proper sieve and added to the powder granulation prepared in Step e and are stirred to obtain a uniform final blend, g. Tablet compression is performed with the final blend in Step f.
The obtained tablets were subjected to in vitro dissolution study and the dissolution conditions were designated considering the gastrointestinal pathway of orally applied solid dosage forms.
The dissolution test is carried out at pH 6.8 phosphate buffer containing 0.05% sodium lauryl sulfate. Other conditions are defined as; volume of dissolution media is 900 ml, temperature is 37°C±0.5°C, rotation speed is 75 rpm, apparatus is paddle and the duration of dissolution study is 60-minute.
Table 2: The results of dissolution study of Example 1
Based on the results presented in Table 1 above, the in-vitro dissolution results of Example 1 were similar with the Reference drug product.
In accordance with FDA regulations, similarity of two drug products can be compared based on the results of in vitro dissolution profile studies of these drug products by using a similarity factor f2. The similarity factor f2 is the most common comparison index and if the estimated value is in the range from 50 to 100, the dissolution profiles of two drug products in comparison are concluded as similar. In the present invention, the similarity factor f2 of Example 1 was calculated as 78.0, wherein the first sample was taken after 10 minutes, which means the developed formulation was suitable and the prepared pharmaceutical composition is proper as it was intended.
Finally, the proper dissolution profile was obtained which was developed in the immediate release dosage form comprising Apixaban having a D90 value less than 20 microns and at least one pharmaceutical excipient manufactured by using wet granulation method, wherein Apixaban was only present in the powder blend and binder solution was made of dissolved povidone and poloxamer which enable the aqueous povidone-based binder solution to decrease the interfacial tension between the poorly soluble Apixaban particles.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Claims
1. A solid oral pharmaceutical composition comprising Apixaban and at least one pharmaceutically acceptable excipient manufactured by using wet granulation method, wherein Apixaban is in crystalline form having a D90 value less than 20 microns and Apixaban is in non-hydrolyzed form.
2. A solid oral pharmaceutical composition according to Claim 1, wherein the Apixaban particles have a D90 value less than 17 microns, preferably less than 15 microns.
3. A solid oral pharmaceutical composition according to claim 1 or 2, wherein at least one pharmaceutically acceptable excipient is selected from fillers, disintegrants, binders, lubricants, granulation solvents, surfactants and mixtures thereof.
4. A solid oral pharmaceutical composition according to Claim 3, wherein at least one pharmaceutically acceptable excipient is a filler, preferably selected from dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
5. A solid oral pharmaceutical composition according to Claim 4, wherein the filler is a combination of lactose anhydrous and microcrystalline cellulose.
6. A solid oral pharmaceutical composition according to Claim 3, wherein at least one pharmaceutically acceptable excipient is a disintegrant, preferably selected from the group comprising croscarmellose sodium, sodium starch gjycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
7. A solid oral pharmaceutical composition according to Claim 6, wherein the disintegrant is croscarmellose sodium.
8. A solid oral pharmaceutical composition according to Claim 3, wherein at least one pharmaceutically acceptable excipient is a binder, preferably selected from hypromellose, sodium carboxymethyi cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol and mixtures thereof.
9. A solid oral pharmaceutical composition according to Claim 8, wherein the binder is povidone.
10. A solid oral pharmaceutical composition according to Claim 3, wherein at least one pharmaceutically acceptable excipient is a lubricant, preferably selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
11. A solid oral pharmaceutical composition according to Claim 10, wherein the lubricant is magnesium stearate.
12. A solid oral pharmaceutical composition according to Claim 3, wherein at least one pharmaceutically acceptable excipient is a granulation solvent, preferably selected from water, ethanol, isopropanol and methylene chloride either alone or in combination.
13. A solid oral pharmaceutical composition according to Claim 12, wherein the granulation solvent is water.
14. A solid oral pharmaceutical composition according to Claim 1, wherein at least one pharmaceutically acceptable excipient is a surfactant, preferably selected from polyoxyethylene fatty alcohol ethers, sorbitan fatty acid esters, stearyl alcohol, poloxamers, potassium laureate, sodium lauryl sulfate, benzalkonium chloride and mixtures thereof.
15. A solid oral pharmaceutical composition according to Claim 14, wherein the surfactant is poloxamer.
16. A solid oral pharmaceutical composition according to any one of the preceding claims wherein the composition comprsing;
17. A wet granulation method for the preparation of a pharmaceutical composition according to any one of the preceding claims, wherein the process comprising the steps of;
a. Apixaban, Lactose monohydrate, Croscarmellose sodium, Microcrystalline cellulose and specified amount of Povidone are screened through a proper sieve, transferred into the high shear mixer and stirred, b. Poloxamer is dissolved in a sufficient amount of the deionized water till to dissolve completely, c. The rest amount of the Povidone is added into the granulation solution prepared in Step b and stirred till to obtain homogenous mixture, d. The solution in Step c is added into the powder blend prepared in Step a to perform granulation process, e. The granule prepared in Step d is dried in fludizied bed dryer and shifted through a proper sieve, f. Magnesium stearate is screened through a proper sieve and added to the powder granulation prepared in Step e and are stirred to obtain a uniform final blend, g. Tablet compression is performed with the final blend in Step f.
18. A solid oral pharmaceutical composition according to any one of the preceding claims, wherein the composition is in the form of tablet.
19. A solid oral pharmaceutical composition according to any one of the preceding claims for use in the treatment of Venous thromboembolism in adults following elective knee or hip replacement surgery and for reducing the risk of stroke or systemic embolism in adults with non-valvular Atrial fibrillation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20963794.1A EP4251155A4 (en) | 2020-11-27 | 2020-11-27 | Improved wet granulation processes for apixaban comprising formulations |
| PCT/TR2020/051185 WO2022115052A1 (en) | 2020-11-27 | 2020-11-27 | Improved wet granulation processes for apixaban comprising formulations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2020/051185 WO2022115052A1 (en) | 2020-11-27 | 2020-11-27 | Improved wet granulation processes for apixaban comprising formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022115052A1 true WO2022115052A1 (en) | 2022-06-02 |
Family
ID=81754730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2020/051185 WO2022115052A1 (en) | 2020-11-27 | 2020-11-27 | Improved wet granulation processes for apixaban comprising formulations |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4251155A4 (en) |
| WO (1) | WO2022115052A1 (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1427415A1 (en) | 2001-09-21 | 2004-06-16 | Bristol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2011106478A2 (en) * | 2010-02-25 | 2011-09-01 | Bristol-Myers Squibb Company | Apixaban formulations |
| EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| CN104644593A (en) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | Apixaban composition and preparation method thereof |
| EP2907507A1 (en) | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| WO2017121340A1 (en) | 2016-01-12 | 2017-07-20 | 广东东阳光药业有限公司 | Araxaban solid composition and preparation method therefor |
| WO2017163170A1 (en) | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
| WO2017182908A1 (en) | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| EP3405195A1 (en) | 2016-01-22 | 2018-11-28 | STADA Arzneimittel AG | Method for producing an apixaban granulate |
| TR201717703A2 (en) | 2017-11-10 | 2019-05-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | APIXABAN FORMULATIONS |
| WO2019177318A1 (en) | 2018-03-13 | 2019-09-19 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical formulation for solubilization comprising apixaban and its preparation method |
| EP3582777A1 (en) | 2017-02-17 | 2019-12-25 | Unichem Laboratories Ltd | Pharmaceutical composition of apixaban |
-
2020
- 2020-11-27 WO PCT/TR2020/051185 patent/WO2022115052A1/en unknown
- 2020-11-27 EP EP20963794.1A patent/EP4251155A4/en active Pending
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1427415A1 (en) | 2001-09-21 | 2004-06-16 | Bristol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2011106478A2 (en) * | 2010-02-25 | 2011-09-01 | Bristol-Myers Squibb Company | Apixaban formulations |
| EP2538925A2 (en) | 2010-02-25 | 2013-01-02 | Bristol-Myers Squibb Company | Apixaban formulations |
| EP3643301A1 (en) | 2010-02-25 | 2020-04-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban formulations |
| EP3257500A1 (en) | 2010-02-25 | 2017-12-20 | Bristol-Myers Squibb Holdings Ireland | Apixaban formulations |
| EP3017811A1 (en) | 2010-02-25 | 2016-05-11 | Bristol-Myers Squibb Company | Apixaban formulations |
| EP3251660A1 (en) | 2010-02-25 | 2017-12-06 | Bristol-Myers Squibb Holdings Ireland | Apixaban formulations |
| EP3246021A1 (en) | 2010-02-25 | 2017-11-22 | Bristol-Myers Squibb Holdings Ireland | Apixaban formulations |
| EP3662899A1 (en) | 2010-02-25 | 2020-06-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban formulations |
| EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| CN104644593A (en) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | Apixaban composition and preparation method thereof |
| EP3107530A1 (en) | 2014-02-17 | 2016-12-28 | Sandoz AG | Pharmaceutical composition comprising apixaban |
| EP2907507A1 (en) | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| WO2017121340A1 (en) | 2016-01-12 | 2017-07-20 | 广东东阳光药业有限公司 | Araxaban solid composition and preparation method therefor |
| EP3405195A1 (en) | 2016-01-22 | 2018-11-28 | STADA Arzneimittel AG | Method for producing an apixaban granulate |
| WO2017163170A1 (en) | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
| WO2017182908A1 (en) | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
| EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| EP3582777A1 (en) | 2017-02-17 | 2019-12-25 | Unichem Laboratories Ltd | Pharmaceutical composition of apixaban |
| TR201717703A2 (en) | 2017-11-10 | 2019-05-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | APIXABAN FORMULATIONS |
| WO2019177318A1 (en) | 2018-03-13 | 2019-09-19 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical formulation for solubilization comprising apixaban and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP4251155A4 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4251155A4 (en) | 2024-07-31 |
| EP4251155A1 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3914252B1 (en) | Pharmaceutical compositions of nilotinib | |
| EP1239831B1 (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
| EP2331074B1 (en) | Granulates, process for preparing them and pharmaceutical products containing them | |
| US5900425A (en) | Pharmaceutical preparations having controlled release of active compound and processes for their preparation | |
| JP5769963B2 (en) | Pharmaceutical compositions containing dihydropyridine calcium channel antagonists and methods for their preparation | |
| EP2907507A1 (en) | Pharmaceutical composition comprising apixaban | |
| WO2015124995A1 (en) | Solid dosage forms of rivaroxaban | |
| JP2010513356A (en) | Formulation containing a neurokinin antagonist | |
| US11679105B1 (en) | Pharmaceutical compositions of cabozantinib | |
| EP2242483A1 (en) | Raloxifene composition | |
| US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
| AU2009251563A1 (en) | Raloxifene pharmaceutical formulations | |
| WO2022115052A1 (en) | Improved wet granulation processes for apixaban comprising formulations | |
| WO2021239893A1 (en) | Amorphous solid dispersion of acalabrutinib | |
| EP4251271A1 (en) | Direct compression method for non-micronised apixaban formulations | |
| JP2009538905A (en) | Stable formulation comprising moisture sensitive drug and method for producing the same | |
| US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
| EP4279075A1 (en) | A pharmaceutical composition comprising elagolix | |
| TW202435886A (en) | Milvexian pharmaceutical compositions | |
| EP3162368A1 (en) | Pharmaceutical composition for oral administration | |
| WO2022199896A1 (en) | Pharmaceutical composition comprising rivaroxaban and method of preparation thereof | |
| WO2024167899A1 (en) | Milvexian pharmaceutical compositions | |
| JP2024532885A (en) | Pharmaceutical compositions and methods for preparing same | |
| WO2024136768A1 (en) | Stable pharmaceutical compositions comprising amorphous tolvaptan | |
| WO2024191389A1 (en) | A pharmaceutical composition of regorafenib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20963794 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020963794 Country of ref document: EP Effective date: 20230627 |